Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 5,126 matching trials from the live ClinicalTrials.gov search.

Filters: San Francisco, California Clear all

Conditions: HIV Infections, HIV Wasting Syndrome
Interventions: Thalidomide; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 13
States / cities: Greenbrae, California • Redwood City, California • San Diego, California + 9 more

Conditions: Multiple Myeloma, Stem Cell Transplant
Interventions: Pack Health's Digital Life Coaching (DLC), Electronic Handouts; Behavioral · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Anterior Cruciate Ligament Injury, Anterior Cruciate Ligament Reconstruction, Joint Instability
Interventions: Anterior cruciate ligament reconstruction (ACLR), Lateral extra-articular tenodesis (LET); Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years to 25 Years
Enrollment: 1,272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 14
States / cities: Redwood City, California • San Francisco, California • Orlando, Florida + 11 more

Conditions: Insulin Resistance, Oxidative Stress
Interventions: Alpha Lipoic Acid; Dietary Supplement
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Insomnia, Depression
Interventions: Digital CBT-I, Digital SHE; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis
Interventions: Motivational Interview, Video Attention Control; Behavioral · Other
Lead sponsor: The Hospital for Sick Children; Other
Eligibility: 10 Years to 18 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 11
States / cities: Birmingham, Alabama • Loma Linda, California • San Francisco, California + 8 more

Conditions: Recurrent Glioblastoma, Recurrent Adult Brain Tumor, Gliosarcoma
Interventions: HSPPC-96, bevacizumab; Biological · Drug
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 417
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 268 more

Conditions: Tobacco Dependence, Tobacco Smoking
Interventions: Smoke-free home resident intervention, Lay Health Worker coaching; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Myeloma
Interventions: Elranatamab, Elotuzumab, Pomalidomide, Dexamethasone, Bortezomib, Carfilzomib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 492 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 100
States / cities: Mobile, Alabama • Goodyear, Arizona • Beverly Hills, California + 55 more

Conditions: Melanoma (Skin)
Interventions: vinorelbine; Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 86
States / cities: Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 56 more

Conditions: COVID-19
Interventions: Obeldesivir, Obeldesivir Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 12 Years to 64 Years
Enrollment: 2,011 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 108
States / cities: Alabaster, Alabama • Chandler, Arizona • Tucson, Arizona + 60 more

Conditions: Lung Cancer
Interventions: chromogenic in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, polymorphism analysis, fluorescent antibody technique, immunohistochemistry staining method, laboratory biomarker analysis, matrix-assisted laser desorption/ionization time of flight mass spectrometry, study of socioeconomic and demographic variables, study of high risk factors; Genetic · Other · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years to 120 Years
Enrollment: 981 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 405
States / cities: Anchorage, Alaska • Tucson, Arizona • Fort Smith, Arkansas + 279 more

Conditions: Myelodysplastic Syndromes
Interventions: Magrolimab, Azacitidine, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 539 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 47
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Duarte, California + 32 more

Conditions: HIV Preexposure Prophylaxis
Interventions: ISL, FTC/TDF, FTC/TAF, Placebo to ISL, Placebo to FTC/TDF, Placebo to FTC/TAF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older · Male only
Enrollment: 494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more

Conditions: Aspergillosis, Invasive Fungal Infection
Interventions: Isavuconazole, Voriconazole; Drug
Lead sponsor: Astellas Pharma Inc; Industry
Eligibility: 18 Years and older
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 11
States / cities: Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 7 more

Conditions: Hereditary Hemorrhagic Telangiectasia
Interventions: Not listed
Lead sponsor: Unity Health Toronto; Other
Eligibility: Not listed
Enrollment: 2,272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2025
U.S. locations: 14
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more

Conditions: Coronary Artery Disease
Interventions: Shockwave Medical Coronary IVL System; Device
Lead sponsor: Shockwave Medical, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 34
States / cities: Loma Linda, California • Los Angeles, California • San Francisco, California + 26 more

Conditions: Maxillary Sinusitis
Interventions: Specimen collection; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Interventions: Lorlatinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 49
States / cities: Sedona, Arizona • Huntington Beach, California • Irvine, California + 30 more

Conditions: Metastasis, Breast Cancer
Interventions: NKTR-102, Eribulin, Ixabepilone, Vinorelbine, Gemcitabine, Paclitaxel, Docetaxel, Nab-paclitaxel; Drug
Lead sponsor: Nektar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 178 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 19
States / cities: Tucson, Arizona • Orange, California • San Francisco, California + 16 more

Conditions: Participants Must be Women Aged 25 Years or Older, Participants Should Have no Self-reported History of Heart Disease or Stroke, Participants Should Have no Terminal Illness or Diagnosed Cognitive Impairment, Including Alzheimer's Disease, Participants Should Not be a Healthcare Professionals or Healthcare Trainees, Participants Should Not be Employed in the Healthcare Field, Participants Should Reside in the United States and be a University of California, San Francisco Health Patient, Participants Should Possess a Smartphone With an Active Data Plan or Access to Wi-Fi
Interventions: HeartBot II Program, Waitlist Control; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 25 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Aortic Stenosis, Aortic Stenosis, Severe
Interventions: Edwards SAPIEN 3/SAPIEN 3 Ultra THV; Device
Lead sponsor: Edwards Lifesciences; Industry
Eligibility: Not listed
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2038
U.S. locations: 50
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 43 more

Conditions: Breast Cancer, Colorectal Cancer
Interventions: Telephone-Based exercise intervention; Behavioral
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2026
U.S. locations: 9
States / cities: La Jolla, California • San Francisco, California • Boston, Massachusetts + 6 more

Conditions: Hemophilia A
Interventions: SB-525 (PF-07055480); Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 22
States / cities: Little Rock, Arkansas • Duarte, California • Sacramento, California + 7 more

Search by objective public record fields.

A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome

Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation

STABILITY 2: Anterior Cruciate Ligament Reconstruction +/- Lateral Tenodesis With Patellar vs Quad Tendon

Alpha Lipoic Acid and Polycystic Ovary Syndrome

Perinatal Research on Improving Sleep and Mental Health

Adherence in Pediatric Multiple Sclerosis

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Smoke-free Home Study in Subsidized Housing

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

Study of Obeldesivir in Nonhospitalized Participants With COVID-19

S0424 - Carcinogens in Lung Tissue From Smokers (Closed to Entry as of 7/15/07) and Non-Smokers With Newly Diagnosed Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Isavuconazole (BAL8557) for Primary Treatment of Invasive Aspergillosis

Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

Equity in Modifying Plaque Of WomEn With UndeRtreated Calcified Coronary Artery Disease

Microarray Analysis of Sinus Samples From Patients With and Without Chronic Rhinosinusitis

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine

RCT of HeartBot in Women

PARTNER 3 Trial - Aortic Valve-in-Valve

The Active After Cancer Trial (AACT)

A Study of Recombinant AAV2/6 Human Factor 8 Gene Therapy SB-525 (PF-07055480) in Subjects With Severe Hemophilia A